Data Insights

(Dexborneol + edaravone) by Simcere Pharmaceutical Group for Acute Ischemic Stroke: Likelihood of Approval

(Dexborneol + edaravone) is under clinical development by Simcere Pharmaceutical Group and currently in Phase I for Acute Ischemic Stroke....

Likelihood of Approval and Phase Transition Success Rate Model - (Dexborneol + Edaravone) in Acute Ischemic Stroke

Data Insights

Endostatin by Simcere Pharmaceutical Group for Ascites: Likelihood of Approval

Endostatin is under clinical development by Simcere Pharmaceutical Group and currently in Phase III for Ascites. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Endostatin in Ascites

Data Insights

Endostatin by Simcere Pharmaceutical Group for Malignant Pleural Effusion: Likelihood of Approval

Endostatin is under clinical development by Simcere Pharmaceutical Group and currently in Phase III for Malignant Pleural Effusion. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Endostatin in Malignant Pleural Effusion

Data Insights

Endostatin by Simcere Pharmaceutical Group for Nasopharyngeal Cancer: Likelihood of Approval

Endostatin is under clinical development by Simcere Pharmaceutical Group and currently in Phase II for Nasopharyngeal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Endostatin in Nasopharyngeal Cancer